五星体育直播

五星体育直播 Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides

Collaboration with Merck published in Science magazine

REDWOOD CITY, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- 五星体育直播 (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announces the publication with Merck, known as MSD outside the United States and Canada, of a paper in the peer-reviewed journal Science, detailing the development of a suite of enzymes and their application for site-selective synthesis of insulin bioconjugates.

鈥淥ur ongoing agreement with Merck has produced multiple scientific breakthroughs in the enzyme engineering field. This work described in Science is another great example of how scientific collaboration can effectively address challenges facing the biotech industry,鈥� said John Nicols, 五星体育直播鈥� President and CEO. 鈥淭he development of this toolbox of enzymes opens opportunities for generating new clinical leads not before possible.鈥�

罢丑别听 describes the development and optimization of enzymes using 五星体育直播鈥� proprietary CodeEvolver庐 technology platform. Each enzyme has unique specificity and was evaluated for its ability to modify insulin. The described work highlights how enzymes can be engineered to functionalize peptides in a targeted fashion beyond that possible with conventional chemical approaches.

鈥淭he ability to specifically target chemical moieties along a peptide chain provides wide-ranging possibilities for future protein modification,鈥� said Ania Fryszkowska, Ph.D., Director, Biocatalysis, Enabling Technologies, Merck Research Laboratories and a corresponding author on the publication.

About 五星体育直播

五星体育直播 is a leading enzyme engineering company leveraging its proprietary CodeEvolver庐 platform to discover and develop novel, high performance enzymes and novel biotherapeutics. 五星体育直播 enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and oral enzyme therapies. The company鈥檚 unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. 五星体育直播 enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit .

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding 五星体育直播, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond 五星体育直播鈥� control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in 五星体育直播鈥� Annual Report on Form 10-K filed with the Securities and Exchange Commission (鈥淪EC鈥�) on February 28, 2022, including under the caption 鈥淩isk Factors,鈥� in 五星体育直播鈥� Quarterly Report on Form 10-Q filed with the SEC on May 9, 2022, and in 五星体育直播鈥� other periodic reports filed with the SEC. 五星体育直播 expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Relations Contact:

Argot Partners
Brendan Strong/Carrie McKim
(212) 600-1902

Released June 17, 2022